<- Go Home
Summit Therapeutics Inc.
Summit Therapeutics Inc., a biopharmaceutical company, focuses on discovery, development, and commercialization of patient, physician, caregiver, and societal friendly medicinal therapies. Its lead development candidate is ivonescimab, a bispecific antibody for immunotherapy through blockade of PD-1 with the anti-angiogenesis, as well as in Phase III clinical trials for the treatment of non-small lung cancer. The company was founded in 2003 and is headquartered in Miami, Florida.
Market Cap
$13.4B
Volume
3.5M
Cash and Equivalents
$238.6M
EBITDA
-$935.0M
Tax Rate Collected
N/A
Tax Rate Ratio
N/A
Gross Profit
N/A
Profit Margin
N/A
52 Week High
$36.91
52 Week Low
$15.55
Dividend
N/A
Price / Book Value
69.81
Price / Earnings
-14.42
Price / Tangible Book Value
70.55
Enterprise Value
$13.2B
Enterprise Value / EBITDA
-14.17
Operating Income
-$935.1M
Return on Equity
292.49%
Return on Assets
-152.88
Cash and Short Term Investments
$238.6M
Debt
$5.4M
Equity
$192.3M
Revenue
N/A
Unlevered FCF
$73.8M
Sector
Biotechnology
Category
N/A
Hedge Funds that own this stock
PREMIUM
Upgrade to Yellowbrick Premium to unlock the Professional Funds that own this company (and many other perks).
Upgrade to Yellowbrick PremiumYellowbrick Portfolios that own this stock
PREMIUM
Upgrade to Yellowbrick Premium to unlock the Yellowbrick portfolios that own this company (and many other perks).
Upgrade to Yellowbrick Premium